PIFLUFOLASTAT F-18

FDA Drug Profile — PYLARIFY TRUVU, PIFLUFOLASTAT F-18, PYLARIFY

PIFLUFOLASTAT F-18 is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand names including PYLARIFY TRUVU, PIFLUFOLASTAT F-18, PYLARIFY. Available dosage form: injection.

Drug details

Generic Name
PIFLUFOLASTAT F-18
Brand Names
PYLARIFY TRUVU, PIFLUFOLASTAT F-18, PYLARIFY
Application Number
NDA220089
Sponsor
Aphelion LLC
NDC Codes
3
Dosage Forms
INJECTION
Routes
INTRAVENOUS
Active Ingredients
PIFLUFOLASTAT F-18

Indications and Usage

1 INDICATIONS AND USAGE PYLARIFY TRUVU is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level PYLARIFY TRUVU is a radioactive diagnostic drug indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.